TScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings Results

TScan Therapeutics (NASDAQ:TCRX) announced its earnings results on Wednesday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02), Zacks reports. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

TScan Therapeutics Trading Down 2.8 %

TCRX stock traded down $0.06 during midday trading on Wednesday, hitting $1.96. The stock had a trading volume of 61,141 shares, compared to its average volume of 308,761. TScan Therapeutics has a 12-month low of $1.82 and a 12-month high of $9.69. The firm has a market cap of $104.77 million, a PE ratio of -1.84 and a beta of 0.87. The company’s 50-day moving average price is $2.47 and its 200 day moving average price is $4.07. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on TCRX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a research note on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Wednesday, December 11th. Finally, Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a research note on Monday, December 23rd.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.